Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report

Quintino Giorgio D’Alessandris, Nicola Montano, Maurizio Martini, Tonia Cenci, Liverana Lauretti, Vittorio Stumpo, Fabrizio Pignotti, Alessandro Olivi, Eduardo Fernandez, Luigi Maria Larocca, Roberto Pallini

Research output: Contribution to journalArticle

Abstract

Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.

Original languageEnglish (US)
JournalActa Neurochirurgica
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Keywords

  • Bevacizumab
  • Erlotinib
  • Glioblastoma
  • Tailored therapy
  • Targeted therapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report'. Together they form a unique fingerprint.

Cite this